In Conversation

The past six months have been significant. We held two successful high-level meetings, one with Premier Li Keqiang and one with Vice Premier Hu Chunhua. Being…

China has always been a tough and complex market but I would say that in recent years, it has become tougher, notably due to the reforms…

We look forward to the acceleration of registration processes as well as the harmonization of China’s regulatory requirements with more developed and mature countries

You cannot come to China with the expectation that you will copy and paste what you have done in other markets

Here in China, it is equally important to remember to focus on employees and the employee journey. Without happy and productive employees, the company cannot grow!

Now that China is a part of ICH, the Chinese biotech sector will be exposed to uniform global regulatory and technical development standards.

We cannot focus only on the Chinese market. China may be the second-largest pharmaceutical market in the world but it still represents only 10 percent of…

Having the right organization and the right people is critical to success

We have been chosen as ‘IPO of the Year’ by the leading finance magazine in Asia, International Financing Review (IFR) Asia! But in terms of Innovent’s journey,…

This is how I like to look at it: yes, the regulatory system is different here – as it is everywhere. The financial system is different…

The global R&D and innovation system often involves close collaboration between big multinationals, capital and local start-ups – and this sort of environment is developing in…

Brexit does not seem to have had a lot of negative effect on British companies in China. On the contrary, there seems to be a general…